Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

InMed Pharmaceuticals (INM) Operating Leases (2021 - 2025)

Historic Operating Leases for InMed Pharmaceuticals (INM) over the last 5 years, with Q4 2025 value amounting to $123827.0.

  • InMed Pharmaceuticals' Operating Leases fell 7660.32% to $123827.0 in Q4 2025 from the same period last year, while for Dec 2025 it was $123827.0, marking a year-over-year decrease of 7660.32%. This contributed to the annual value of $305755.0 for FY2025, which is 5258.62% down from last year.
  • InMed Pharmaceuticals' Operating Leases amounted to $123827.0 in Q4 2025, which was down 7660.32% from $215478.0 recorded in Q3 2025.
  • In the past 5 years, InMed Pharmaceuticals' Operating Leases registered a high of $1.2 million during Q4 2023, and its lowest value of $15994.0 during Q2 2023.
  • For the 5-year period, InMed Pharmaceuticals' Operating Leases averaged around $459318.9, with its median value being $347626.5 (2022).
  • Its Operating Leases has fluctuated over the past 5 years, first tumbled by 9589.37% in 2023, then skyrocketed by 393191.82% in 2024.
  • Quarter analysis of 5 years shows InMed Pharmaceuticals' Operating Leases stood at $825427.0 in 2021, then plummeted by 77.72% to $183902.0 in 2022, then skyrocketed by 534.56% to $1.2 million in 2023, then plummeted by 54.65% to $529248.0 in 2024, then plummeted by 76.6% to $123827.0 in 2025.
  • Its last three reported values are $123827.0 in Q4 2025, $215478.0 for Q3 2025, and $305755.0 during Q2 2025.